文献速递呼吸道感染

芬兰婴儿10价肺炎球菌结合疫苗接种对成人肺炎住院的群体影响

Population-level impact of infant 10-valent pneumococcal conjugate vaccination on adult pneumonia hospitalisations in Finland.
PubMed 文献 · Thorax · 2017-10-07

该研究评估芬兰2010年引入婴儿PCV10项目前后成人肺炎住院趋势,采用中断时间序列分析。结果显示,PCV10前成人全因肺炎住院率年增2.4%,引入后年降4.7%,2014-2015年住院率较预期低15.4%,≥65岁人群显著下降6.7%。

要点

  • 婴儿PCV10接种后成人全因肺炎住院率由年增2.4%转为年降4.7%。
  • 2014-2015年成人肺炎住院率较预期低15.4%,≥65岁人群降6.7%。
  • 非肺炎住院率全程年降3.5%,提示肺炎下降非全局趋势。

核心结论

  • 婴儿PCV10项目通过群体保护逆转了成人肺炎住院增长趋势并显著降低住院率,尤其老年人。

研究设计与样本

  • 基于芬兰国家登记数据的生态学研究,分析2004-2005至2014-2015年≥18岁成人肺炎住院率。
  • 采用中断时间序列分析和负二项回归模型评估PCV10引入前后趋势变化。

主要发现

  • PCV10前成人全因肺炎住院率年增2.4%,PCV10期间年降4.7%。
  • 2014-2015年总全因肺炎住院率为109.3/10万(95%CI 96.5-121.9),较预期低15.4%。
  • ≥65岁人群肺炎住院率131.5/10万,显著下降6.7%,相当于每年减少1456例住院。
  • 非肺炎住院率全程年降3.5%。

关键数值与推荐

  • PCV10前全因肺炎住院率年增2.4%,PCV10期间年降4.7%。
  • 2014-2015年全因肺炎住院率109.3/10万(95%CI 96.5-121.9),较预期低15.4%。
  • ≥65岁人群肺炎住院率131.5/10万,下降6.7%,每年减少1456例住院。
  • 非肺炎住院率全程年降3.5%。

临床怎么用

  • 支持婴儿PCV10接种通过群体免疫降低成人肺炎住院负担,尤其老年人。
  • 临床可关注老年肺炎住院变化,评估疫苗接种的间接保护效果。

局限性

  • 研究为观察性设计,无法排除其他因素对肺炎住院趋势的影响。
  • 仅基于ICD-10编码的出院诊断,可能存在编码偏倚。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Limited data are available on population-level herd effects of infant 10-valent pneumococcal conjugate vaccine (PCV10) programmes on pneumonia. We assessed national trends in pneumococcal and all-cause pneumonia hospitalisations in adults aged ≥18 years, before and after infant PCV10 introduction in 2010. METHODS: Monthly hospitalisation rates of International Statistical Classification of Diseases, 10th revision (ICD-10)-coded primary discharge diagnoses compatible with pneumonia from 2004-2005 to 2014-2015 were calculated with population denominators from the population register. Trends in pneumonia before and after PCV10 introduction were assessed with interrupted time-series analysis. Rates during the PCV10 period were estimated from adjusted negative binomial regression model and compared with those projected as continuation of the pre-PCV10 trend. All-cause hospitalisations were assessed for control purposes. RESULTS: Before PCV10, the all-cause pneumonia rate in adults aged ≥18 years increased annually by 2.4%, followed by a 4.7% annual decline during the PCV10 period. In 2014-2015, the overall all-cause pneumonia hospitalisation rate was 109.3/100 000 (95% CI 96.5 to 121.9) or 15.4% lower than the expected rate. A significant 6.7% decline was seen in persons aged ≥65 years (131.5/100 000), which translates to 1456 fewer pneumonia hospitalisations annually. In comparison, hospitalisations other than pneumonia decreased by 3.5% annually throughout the entire study period. CONCLUSION: These national data suggest that herd protection from infant PCV10 programme has reversed the increasing trend and substantially decreased all-cause pneumonia hospitalisations in adults, particularly the elderly.

来源:Thorax,查看原文。版权归原作者所有。

引用

  1. Okasha O, Rinta-Kokko H, Palmu AA, et al. Population-level impact of infant 10-valent pneumococcal conjugate vaccination on adult pneumonia hospitalisations in Finland. Thorax. 2017. PMID: 28988217. doi:10.1136/thoraxjnl-2017-210440

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。